EditorialReliability of Ventricular Remodeling as a Surrogate for Use in Conjunction With Clinical Outcomes in Heart Failure
References (46)
- et al.
Ventricular remodeling in heart failurea credible surrogate endpoint
J Card Failure
(2003) - et al.
Surrogate endpoints in heart failure
J Am Coll Cardiol
(2002) - et al.
Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin-converting enzyme inhibition
Lancet
(1991) - et al.
Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)
Lancet
(1997) - et al.
Effect of losartan compared with captopril on mortality in patients with symptomatic heart failurerandomised trial—the Losartan Heart Failure Survival Study ELITE II
Lancet
(2000) - et al.
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitorsthe CHARM-Alternative trial
Lancet
(2003) - et al.
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitorsthe CHARM-Added trial
Lancet
(2003) - et al.
Effects of candesartan on mortality and morbidity in patients with chronic heart failurethe CHARM-Overall programme
Lancet
(2003) - et al.
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fractionthe CHARM-Preserved trial
Lancet
(2003) - et al.
Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarctionthe OPTIMAAL randomised trial
Lancet
(2002)
Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failureresults of the ELITE ventricular function substudy
Am Heart J
Valsartan benefits left ventricular structure and function in heart failureVal-HeFT echocardiographic study
J Am Coll Cardiol
Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors
J Am Coll Cardiol
Severity of left ventricular remodeling defines outcomes and response to therapy in heart failureValsartan Heart Failure Trial (Val-HeFT) echocardiographic data
J Am Coll Cardiol
Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade
J Am Coll Cardiol
Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group
J Am Coll Cardiol
Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure
J Am Coll Cardiol
Remodeling as an end-point in heart failure therapy
Cardiovasc Drugs Ther
Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure
Circulation
Echocardiographic variables as prognostic indicators and therapeutic monitors in chronic congestive heart failureVeterans Affairs cooperative studies V-HeFT I and II
Circulation
Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction
N Engl J Med
ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure)
Circulation
Cited by (46)
Transcatheter Left Ventricular Restoration in Patients With Heart Failure
2023, Journal of Cardiac FailureHeart failure with recovered ejection fraction: Current understanding and future prospects
2023, American Journal of the Medical SciencesClinical significance of ischemia-like electrocardiographic finding during heart failure treatment on left ventricular recovery in patients with non-ischemic dilated cardiomyopathy
2021, Journal of CardiologyCitation Excerpt :LV remodeling is a major pathogenic mechanism in heart failure (HF) progression and a predictor of prognosis [2]. The inverse process, left ventricular reverse remodeling (LVRR), characterized by a reduction in LV volume and an improvement in LV systolic function, is related to favorable long-term prognosis [3], derived either spontaneously [4] or after the introduction of neurohumoral therapy [5,6]. Previous studies showed that various factors such as sex [7], serum markers [8], genetic basis [9], echocardiographic indices [10–12], and late gadolinium enhancement in cardiac magnetic resonance imaging (CMR) [13,14] predicted LVRR in patients with HF.
Systolic function recovery in Heart Failure: Frequency, prognostic impact and predictors
2020, International Journal of CardiologyGenetic determinants of responsiveness to mesenchymal stem cell injections in non-ischemic dilated cardiomyopathy
2019, EBioMedicineCitation Excerpt :Since a significant proportion of the NIDCM population burden appears to be familial, and are associated with variants in specific genes [2,3], we sought to test the hypothesis that genetic factors predict clinical responses and correlate with patient recovery. Improvement of left ventricle function (LV) and/or restoration of LV geometry, referred to as reverse remodeling, is associated with improved quality of life (QOL) [4], and with reductions in mortality [5], left ventricular assist device (LVAD) implantation, heart transplants, and hospitalization [6]. The therapeutic response of HFrecEF is a recognized outcome with improved prognosis compared to HF with a persistently reduced EF [7].
Heart Failure with Myocardial Recovery - The Patient Whose Heart Failure Has Improved: What Next?
2017, Progress in Cardiovascular DiseasesCitation Excerpt :Also, myocardial recovery is more likely in patients with a shorter duration and less myocardial fibrosis.19,43 Improvement of LVEF has been systematically linked to improved quality of life and lower rehospitalization rates and mortality, regardless of how it is achieved.20 HFrecEF patients have often milder symptoms, with patients mainly functioning in New York Heart Association (NYHA) class I or II.17
This study was supported by a grant from Novartis Pharmaceuticals, East Hanover, New Jersey.